Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid… Read more
Inhibrx Biosciences, Inc. (INBX) - Total Assets
Latest total assets as of September 2025: $177.47 Million USD
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) holds total assets worth $177.47 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Inhibrx Biosciences, Inc. - Total Assets Trend (2016–2024)
This chart illustrates how Inhibrx Biosciences, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Inhibrx Biosciences, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Inhibrx Biosciences, Inc.'s total assets of $177.47 Million consist of 88.7% current assets and 11.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.4% |
| Accounts Receivable | $420.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Inhibrx Biosciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inhibrx Biosciences, Inc.'s current assets represent 88.7% of total assets in 2024, a decrease from 95.9% in 2016.
- Cash Position: Cash and equivalents constituted 84.4% of total assets in 2024, down from 94.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Inhibrx Biosciences, Inc. Competitors by Total Assets
Key competitors of Inhibrx Biosciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Inhibrx Biosciences, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Inhibrx Biosciences, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Inhibrx Biosciences, Inc. generates $ 933.56 in net profit.
Inhibrx Biosciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.49 | 4.70 | 4.21 |
| Quick Ratio | 4.49 | 4.70 | 8.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $125.44 Million | $ 163.35 Million | $ 100.77 Million |
Inhibrx Biosciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Inhibrx Biosciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.24 |
| Latest Market Cap to Assets Ratio | 2.99 |
| Asset Growth Rate (YoY) | -41.3% |
| Total Assets | $180.77 Million |
| Market Capitalization | $539.70 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Inhibrx Biosciences, Inc.'s assets at a significant premium ( 2.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Inhibrx Biosciences, Inc.'s assets decreased by 41.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Inhibrx Biosciences, Inc. (2016–2024)
The table below shows the annual total assets of Inhibrx Biosciences, Inc. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $180.77 Million | -41.29% |
| 2023-12-31 | $307.89 Million | +5.85% |
| 2022-12-31 | $290.88 Million | +93.34% |
| 2021-12-31 | $150.45 Million | +4.67% |
| 2020-12-31 | $143.74 Million | +442.64% |
| 2019-12-31 | $26.49 Million | +165.31% |
| 2018-12-31 | $9.98 Million | -42.11% |
| 2017-12-31 | $17.25 Million | -18.93% |
| 2016-12-31 | $21.27 Million | -- |